Please use this identifier to cite or link to this item:
Title: Parameters for using mannan-MUC1 fusion protein to induce cellular immunity.
Austin Authors: Pietersz, Geoffrey A;Li, W;Popovski, V;Caruana, J A;Apostolopoulos, V;McKenzie, Ian F C
Affiliation: The Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Feb-1998
Publication information: Cancer Immunology, Immunotherapy : Cii; 45(6): 321-6
Abstract: We have previously reported preclinical studies in mice of the human mucin 1 (MUC1) antigen covalently linked to the yeast cell-wall mannan polysaccharide (MFP), and shown strong cellular responses of the T1 type using mice. We now describe the optimum parameters for administration of MFP to obtain cellular immunity [as measured by the cytotoxic T cell precursor (CTLp) frequency]. In dose/response studies, in which 1 microg-150 microg was given by the i.p. route, it was clear that doses of 1-7 microg led to cellular and not humoral immunity; at doses above 7 microg humoral immunity prevailed with little cellular immunity increasing doses giving greater amounts of antibody. The most favoured routes of administration were intraperitoneal or intradermal immunisation, which were substantially better than i.m., i.v.; s.c. administration was the worst. Three immunisations were necessary for a maximum cellular response, further immunisation decreasing the CTLp frequency. Six different adjuvants were used with MFP [complete and incomplete Freund's adjuvant (CFA, IFA) Alum, Adjuprime, muramyl dipeptide (MDP) and glutaminyl-muramyl dipeptide (GMDP)]; Alum, GMDP, MDP and IFA moderately increased the CTLp frequency, IFA being the best. Even though preclinical studies of the immunogen in mice may not necessarily mirror the behaviour of the immunogen in humans, these studies demonstrate the factors to be taken into account for phase I/II clinical trials.
Gov't Doc #: 9490202
Journal: Cancer immunology, immunotherapy : CII
Type: Journal Article
Subjects: Animals
Cytotoxicity, Immunologic
Dose-Response Relationship, Immunologic
Drug Administration Routes
Immunity, Cellular.immunology
Immunization Schedule
Mice, Inbred BALB C
T-Lymphocytes, Cytotoxic.immunology
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.